Any current/future new fundraising through debt or equity?

As per the transcript of the earnings call held on 2 August 2024, Hester Biosciences mentioned that: - The current capacity utilization in India is near full, and the CAPEX for expansion has already been incurred. - There is no planned CAPEX for increasing capacity in Africa or Nepal at this point. - They do not foresee the need for additional spending on capacity in the near term. There was no mention or indication of any new fundraising plans through debt or equity in the current or near future. The company emphasized focusing on optimizing existing capacity and maintaining an upward t

Any current/future capex/capital investment/strategic investment?

No additional CAPEX planned for Africa and Nepal; existing capacities deemed sufficient. In India, the company recently expanded capacity; related CAPEX has already been incurred. The expanded capacity at the India facility, including increased freeze-drying capacity, will come into operation in Q3 FY25. Minor modifications planned to repurpose a BSL-3 facility (originally for COVID bulk antigen) for animal vaccines without significant CAPEX. Focus on leveraging existing capacity and pipeline products rather than major new capital investments. No specific investment planned in the pe

Future growth expectations in sales/revenue/volumes?

Q1 FY25 showed strong foundation with 36% quarter-on-quarter standalone sales growth and 34% consolidated sales growth. Poultry Healthcare division grew 35% in Q1, driven by recovery in the poultry industry and focus on vaccines. Animal Healthcare division saw 41% growth, boosted by positive dairy sector trends. Petcare division achieved 29% growth, with increased penetration in vet clinics and new product launches. Africa business is expected to grow geometrically, with improving orders and distribution network. Capacity expansions in India (freeze-drying capacity doubling) expected

Future growth expectations in earnings/operating earnings/profits/EPS?

Q1 FY25 set a strong foundation with 36% quarter-on-quarter standalone sales growth and improved profitability. The company is on an upward trend in topline and bottomline, aiming to maintain this positive trajectory throughout FY25. Margins have shown significant improvement in Q1, with 21% operating margins considered sustainable for the foreseeable future. There is a focus on expanding healthcare-related products in pet division and large animal vaccine R&D, supporting diversified growth. New capacity expansion in India (freeze-drying capacity more than doubled by Q3) will enable re

Current/ Expected Orderbook/ Pending Orders?

Rajiv Gandhi mentioned that worldwide PPR vaccine sales have been lower due to diverted funding (e.g., to COVID), but there is now a positive upward movement in PPR orders. In Africa, there is extremely high visibility of orders from both private sector and government tenders. The African market is challenging, but Hester is confident about geometric progression in order growth due to its distribution network. Tanzania and some other countries are starting to budget for PPR vaccines themselves, reducing dependency on international funding. Q3 and Q4 results are expected to demonstrate good pro

Hester BiosQ1 FY25Pharmaceuticals & Biotechnology

Hester Bios Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹2,127P/E: 35.0Market Cap: ₹1.9K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

Q1 FY25 showed strong foundation with 36% quarter-on-quarter standalone sales growth and 34% consolidated sales growth.
Poultry Healthcare division grew 35% in Q1, driven by recovery in the poultry industry and focus on vaccines.
Animal Healthcare division saw 41% growth, boosted by positive dairy sector trends.
Petcare division achieved 29% growth, with increased penetration in vet clinics and new product launches.
Africa business is expected to grow geometrically, with improving orders and distribution network.
Capacity expansions in India (freeze-drying capacity doubling) expected by Q3 FY25 to support higher volumes without new CAPEX.
Launch of Avian Influenza Vaccine expected in Q4 FY25 or Q1 FY26 expected to drive future poultry vaccine growth.
Management optimistic about sustaining upward topline and bottom-line trends through FY25 and beyond, without giving formal guidance.

Margin guidance

Category 3

Q1 FY25 set a strong foundation with 36% quarter-on-quarter standalone sales growth and improved profitability.
The company is on an upward trend in topline and bottomline, aiming to maintain this positive trajectory throughout FY25.
Margins have shown significant improvement in Q1, with 21% operating margins considered sustainable for the foreseeable future.
There is a focus on expanding healthcare-related products in pet division and large animal vaccine R&D, supporting diversified growth.
New capacity expansion in India (freeze-drying capacity more than doubled by Q3) will enable revenue growth without immediate additional CAPEX.
Africa operations expected to grow geometrically, benefiting from increased orders and improved distribution channels.
No explicit formal guidance given, but management optimistic about sustaining growth and margin improvements over FY25 and beyond.

See what Hester Bios management said on margin guidance — free account, 30 seconds.

Fundraise plans

As per the transcript of the earnings call held on 2 August 2024, Hester Biosciences mentioned that:
- The current capacity utilization in India is near full, and the CAPEX for expansion has already been incurred.
- There is no planned CAPEX for increasing capacity in Africa or Nepal at this point.
- They do not foresee the need for additional spending on capacity in the near term.
There was no mention or indication of any new fundraising plans through debt or equity in the current or near future.
The company emphasized focusing on optimizing existing capacity and maintaining an upward trend in revenues and margins without additional capital raising.

Order book

Yes

Rajiv Gandhi mentioned that worldwide PPR vaccine sales have been lower due to diverted funding (e.g., to COVID), but there is now a positive upward movement in PPR orders.
In Africa, there is extremely high visibility of orders from both private sector and government tenders.
The African market is challenging, but Hester is confident about geometric progression in order growth due to its distribution network.
Tanzania and some other countries are starting to budget for PPR vaccines themselves, reducing dependency on international funding.
Q3 and Q4 results are expected to demonstrate good progress, reflecting improved order flow and business.
Overall, agencies like FAO emphasize capacity enhancement anticipating large PPR vaccine demand in future.

See what Hester Bios management said on order book — free account, 30 seconds.

Capex plans

No additional CAPEX planned for Africa and Nepal; existing capacities deemed sufficient.
In India, the company recently expanded capacity; related CAPEX has already been incurred.
The expanded capacity at the India facility, including increased freeze-drying capacity, will come into operation in Q3 FY25.
Minor modifications planned to repurpose a BSL-3 facility (originally for COVID bulk antigen) for animal vaccines without significant CAPEX.
Focus on leveraging existing capacity and pipeline products rather than major new capital investments.
No specific investment planned in the pet division currently; focus is on introducing new healthcare-related products rather than CAPEX.
Strategic investments include building distribution channels in Africa via subsidiary and invested company Trishul Exim.

Track Hester Bios — get its next earnings analysis in your feed

How does Hester Bios rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisHester Bios

Rev 2Mar 3

See where Hester Bios sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Hester Bios rank in Pharmaceuticals & Biotechnology?

Compare Hester Bios against every Pharmaceuticals & Biotechnology company (Q1 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Hester Bios's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →